Target e*CRF® and Stimulus Funding From NIH

Target Health is pleased to announce that it is part of a clinical trial program now being supported by Federal Stimulus Funds. The clinical trial, Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA; Identifier – NCT00443430; PI, Carol A. Wallace, MD.), was started in 2007 and is using Target e*CRF® for electronic data capture (EDC). Original funding was by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and most recently by Amgen. The study is a multicenter, randomized, parallel, double blind study evaluating methotrexate, etanercept, and prednisolone, versus methotrexate plus placebo etanercept and placebo prednisolone, in newly diagnosed subjects with polyarticular juvenile idiopathic arthritis, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, extended oligoarthritis juvenile idiopathic arthritis. The additional funding will allow for 1) the extension of the clinical trial enrollment period and thus the ability to obtain the full complement of study subjects, and 2) the creation of a biorespository with precious biologic samples from the subjects at key time points in their treatment.

Target Health Inc. is committed to working with academia in early stage development programs and anticipates additional stimulus funding with programs at Rutgers/UMDNJ and SUNY Stony Brook. There is an ongoing EDC program with the Cleveland Clinic, and an EDC program in jaundice in the newborn was recently completed with Stanford University.

For more information about Target Health and our software tools for paperless clinical trials, please contact Dr. Jules T. Mitchel (212-681-2100 ext 0) or Ms. Joyce Hays. Target Health’s software tools are designed to partner with both CROs and Sponsors. Please visit the Target Health Website at


Leave a Reply

You must be logged in to post a comment.